Redhill Biophrma ADR (RDHL) Stock Price, Quote & News

Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear ra...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 972 3 541 3131

Fax: 972 3 541 3144

Website: www.redhillbio.com

Address:

21 Ha’arba’a Street, Tel Aviv, Israel

cryptoish Feb. 19 at 2:41 PM

$RDHL delist this bullshit. And oh yeah , rot in hell ! Fcking genocide company

0 · Reply

FrankScott130 Feb. 18 at 2:00 PM

$RDHL Biotech with clinical setbacks risk.

0 · Reply

sweepjosh Feb. 17 at 8:42 AM

$RDHL Micro-cap biotech; commercial-stage

0 · Reply

DonZulu Feb. 13 at 8:14 PM

$RDHL 3$ target from here

0 · Reply

tatanka9 Feb. 12 at 4:01 PM

$RDHL REDSCAM!!!

0 · Reply

Patrick2343 Feb. 11 at 6:49 PM

$RDHL Opaganib is being evaluated for its potential to treat acute respiratory distress syndrome (ARDS) caused by viruses such as COVID-19 and influenza. Data from the global Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia offer a compelling rationale for further investigation into opaganib’s potential in treating virus-induced ARDS, potentially supporting a Phase 2/3 study in this indication. I forgot about this one. Another scam. Not one thing in the pipeline is legit its all fluff to do pump an dumps. The only legit thing they have is talicia and the sales of that stink.

0 · Reply

Patrick2343 Feb. 11 at 6:44 PM

$RDHL Headed for another reverse split. Might be time for a totally worthles PR.

0 · Reply

Momikhan Feb. 11 at 5:21 PM

$RDHL RED HIll Reverse Split Pharam should be the correct name.

0 · Reply

therealchorris Feb. 11 at 4:02 PM

$RDHL Worst stock ever 🥴

0 · Reply

Patrick2343 Feb. 10 at 11:04 PM

$RDHL Below a buck again and the march towards the next reverse splits is coming

0 · Reply

What's Going On With Redhill Biopharma Stock On Tuesday?

Jan 5, 2026, 7:00 AM EST - 6 weeks ago

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

Dec 15, 2025, 7:00 AM EST - 2 months ago

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

Dec 1, 2025, 7:00 AM EST - 2 months ago

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

Nov 4, 2025, 9:30 AM EST - 3 months ago

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

Oct 22, 2025, 4:50 PM EDT - 4 months ago

RedHill Biopharma Receives Nasdaq Staff Determination Notification

Oct 20, 2025, 9:05 AM EDT - 4 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

CPIX

Oct 6, 2025, 8:00 AM EDT - 4 months ago

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

Sep 29, 2025, 7:00 AM EDT - 5 months ago

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

Sep 5, 2025, 7:00 AM EDT - 5 months ago

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

Aug 20, 2025, 9:00 AM EDT - 6 months ago

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

Aug 18, 2025, 9:00 AM EDT - 6 months ago

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

Jul 21, 2025, 9:00 AM EDT - 7 months ago

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

Jul 1, 2025, 12:00 PM EDT - 8 months ago

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

May 13, 2025, 7:00 AM EDT - 10 months ago

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

May 2, 2025, 7:00 AM EDT - 10 months ago

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

Apr 28, 2025, 7:03 AM EDT - 10 months ago

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

Apr 17, 2025, 4:01 PM EDT - 11 months ago

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Apr 16, 2025, 7:00 AM EDT - 11 months ago

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

Apr 10, 2025, 7:48 AM EDT - 11 months ago

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Mar 18, 2025, 7:00 AM EDT - 1 year ago

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Mar 12, 2025, 7:00 AM EDT - 1 year ago

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

Feb 27, 2025, 7:00 AM EST - 1 year ago

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

Feb 25, 2025, 7:00 AM EST - 1 year ago

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

Feb 4, 2025, 7:00 AM EST - 1 year ago

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

Jan 21, 2025, 7:00 AM EST - 1 year ago

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Dec 10, 2024, 7:00 AM EST - 1 year ago

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Dec 2, 2024, 7:00 AM EST - 1 year ago

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

Oct 28, 2024, 7:00 AM EDT - 1 year ago

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

Oct 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

Oct 14, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

Oct 1, 2024, 7:00 AM EDT - 1 year ago

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

Sep 30, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

Sep 9, 2024, 7:00 AM EDT - 1 year ago

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

Sep 5, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 3, 2024, 7:00 AM EDT - 1 year ago

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

Aug 29, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces First Half 2024 Business Highlights

Aug 26, 2024, 7:00 AM EDT - 1 year ago

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Talicia® Launched in the United Arab Emirates

Aug 19, 2024, 8:56 AM EDT - 1 year ago

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

Aug 19, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

Aug 16, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Aug 1, 2024, 7:00 AM EDT - 1 year ago

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

Jul 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

Jul 9, 2024, 8:00 AM EDT - 1 year ago

RedHill Biopharma Terminates License Agreement for Aemcolo®

Jun 3, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

May 6, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

Apr 24, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

Apr 8, 2024, 9:23 AM EDT - 2 years ago

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

Apr 2, 2024, 7:00 AM EDT - 2 years ago

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

cryptoish Feb. 19 at 2:41 PM

$RDHL delist this bullshit. And oh yeah , rot in hell ! Fcking genocide company

0 · Reply

FrankScott130 Feb. 18 at 2:00 PM

$RDHL Biotech with clinical setbacks risk.

0 · Reply

sweepjosh Feb. 17 at 8:42 AM

$RDHL Micro-cap biotech; commercial-stage

0 · Reply

DonZulu Feb. 13 at 8:14 PM

$RDHL 3$ target from here

0 · Reply

tatanka9 Feb. 12 at 4:01 PM

$RDHL REDSCAM!!!

0 · Reply

Patrick2343 Feb. 11 at 6:49 PM

0 · Reply

Patrick2343 Feb. 11 at 6:44 PM

$RDHL Headed for another reverse split. Might be time for a totally worthles PR.

0 · Reply

Momikhan Feb. 11 at 5:21 PM

$RDHL RED HIll Reverse Split Pharam should be the correct name.

0 · Reply

therealchorris Feb. 11 at 4:02 PM

$RDHL Worst stock ever 🥴

0 · Reply

Patrick2343 Feb. 10 at 11:04 PM

$RDHL Below a buck again and the march towards the next reverse splits is coming

0 · Reply

alexioj Feb. 5 at 6:48 PM

$RDHL Any bullish possibilities in the near future? I haven't watched this stock for a while.

2 · Reply

Patrick2343 Feb. 4 at 6:13 PM

$RDHL yeah dilution

0 · Reply

Momikhan Feb. 4 at 2:08 PM

$RDHL Loothill Scam Pharma.

0 · Reply

Momikhan Feb. 2 at 8:39 PM

$RDHL don't buy this stock. This hasn't been traded since a RS in stock market in EU. They have a pattern of dilution and make RS. Dead business only scammers behind thism

0 · Reply

peepthestamp Jan. 24 at 2:41 AM

$RDHL

0 · Reply

DonZulu Jan. 23 at 5:03 PM

$RDHL this is bullish very soon

0 · Reply

tatanka9 Jan. 23 at 4:53 AM

$RDHL Bio Scam!

0 · Reply

Genesys01 Jan. 22 at 11:17 PM

$RDHL 6 million additional shares? Not even I have expected that the dilution would be that much massive. Then this pension plan... How greedy Dror is, that's really outstanding.

1 · Reply

Genesys01 Jan. 22 at 2:13 PM

$RDHL Exactly as I told you: March 5th, 2026 - extraordinary General Meeting of Shareholders to vote for more shares to Dror and for approve an increase of share capital.

0 · Reply

dup007 Jan. 21 at 1:37 PM

$RDHL Redhill Biopharma Ltd 1.38 0.07 (5.34%) Volume: 234,676 Last Trade Time: 8:18:00 AM EST Something's cooking?

1 · Reply

Michl2000 Jan. 20 at 8:01 PM

$RDHL let's take the lid off

0 · Reply

Michl2000 Jan. 20 at 7:59 PM

$RDHL strong resistance at 1.39$

0 · Reply

Market Cap	5.22M
Revenue (ttm)	8.04M
Net Income (ttm)	-8.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-102.86%
Debt to Equity Ratio	0.00

Volume	16,000
Avg Vol	581,992
Day's Range	N/A - N/A
Shares Out	5.11M
Stochastic %K	23%
Beta	4.91
Analysts	Strong Buy
Price Target	$40.00